| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/23/2005 | CN1582943A Clomipramine hydrochloride drops and their preparation |
| 02/23/2005 | CN1582940A Calmazine hydrochloride drops and their preparation |
| 02/23/2005 | CN1582935A Powder injections of namelfene and their preparation |
| 02/23/2005 | CN1582929A Aparkan drops and their preparation |
| 02/23/2005 | CN1582913A Drops of benzohydroxymethylamine and their preparation |
| 02/23/2005 | CN1582908A Tramadol hydrochloride drops and their preparation |
| 02/23/2005 | CN1190491C PRV-gene and use thereof |
| 02/23/2005 | CN1190438C Nabufulin polybasic ester derivative and its production method |
| 02/23/2005 | CN1190437C Pteridine compounds for treatment of psoriasis |
| 02/23/2005 | CN1190433C Phenylpiperazine |
| 02/23/2005 | CN1190432C Piperazing derivatives as 5-HTIB antagonists |
| 02/23/2005 | CN1190424C Quinoline-containing Alpha-ketoamide cysteine and serine protease inhibitors |
| 02/23/2005 | CN1190222C Chinese medicine powder for treating brain atrophy disease |
| 02/23/2005 | CN1190207C Medicine for withdrawal of drug addiction and preparing process thereof |
| 02/23/2005 | CN1190205C Diemailing injection and its preparing process |
| 02/23/2005 | CN1190195C Metaduocine freeze-dried powder injection preparation and its preparation method |
| 02/23/2005 | CN1190189C Transdermal therapeutic system containing pergolide |
| 02/22/2005 | US6858750 Such as Parkinson's syndrome, Alzheimer's disease, Huntington's disease, retinopathia pigmentosa and mitochondrial encephalomyopathy; preferred are dialkyl fumarate, monoalkyl fumarate and is salts |
| 02/22/2005 | US6858740 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses |
| 02/22/2005 | US6858652 Sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
| 02/22/2005 | US6858649 Contacting the cell having the human serotonin receptor subtype 5-HT1A with a quantity of a serotonergic agent possessing 5- HT1A agonist activity sufficient for potentiating the serotonin response within cell |
| 02/22/2005 | US6858646 Administering an antioxidative composition comprising pyruvate, at least one antioxidant and at least one lipid. |
| 02/22/2005 | US6858645 Prevention or the treatment of CNS disorders and related medical disturbances comprising effective amount of the salt according dissolving (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5 -carboxamide in an appropriate |
| 02/22/2005 | US6858642 For use in pharmaceutical, skin-protective and cosmetic formulations |
| 02/22/2005 | US6858640 Tricyclic indole compounds having affinity for serotonin receptor |
| 02/22/2005 | US6858629 Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same |
| 02/22/2005 | US6858626 Cyclic hydroxamic acid as metalloproteinase inhibitors |
| 02/22/2005 | US6858624 Comprises 5,8,14-triazatetracyclo(10.3.1.0.0)-hexadeca-2(11),3,5,7,9-penaene groups; for reducing drug addiction, treating Alzheimer's/Parkinson's diseases, and other nervous system disorders |
| 02/22/2005 | US6858620 For therapy of male erectile dysfunction; female arousal disorder |
| 02/22/2005 | US6858619 Fused heterocyclic compounds |
| 02/22/2005 | US6858613 Central nervous system disorders |
| 02/22/2005 | US6858612 Use of tetrahydropteridine derivatives as no synthase inhibitors |
| 02/22/2005 | US6858604 Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
| 02/22/2005 | US6858603 Acetindine derivatives, their preparation and medicaments containing them |
| 02/22/2005 | US6858602 Compounds for the treatment of metabolic disorders |
| 02/22/2005 | US6858600 Used for inhibiting the interaction of an alpha-helical protein with another protein or binding site; for therapy of diseases |
| 02/22/2005 | US6858597 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 02/22/2005 | US6858594 Compounds and methods for treating urinary incontinence |
| 02/22/2005 | US6858235 Antioxidant composition and method of preparation thereof |
| 02/22/2005 | US6858228 Compression of drug and adjuvant |
| 02/22/2005 | US6858018 Iontophoretic devices |
| 02/22/2005 | CA2438032A1 Benzothiazole derivative compounds, compositions and uses |
| 02/22/2005 | CA2218493C Benzimidazole compounds and their use as modulators of the gabaa receptor complex |
| 02/17/2005 | WO2005014625A1 Polypeptides having brain disposition activity and utilization of the same |
| 02/17/2005 | WO2005014597A1 N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO |
| 02/17/2005 | WO2005014596A1 7-substituted 3-nitro-pyrazolo `1,5-a! pyrimidines |
| 02/17/2005 | WO2005014584A1 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparation and use as modulators of apoptosis |
| 02/17/2005 | WO2005014578A1 Phenylsulfonyl compounds as antipsychotic agents |
| 02/17/2005 | WO2005014576A1 Isoquinolinone derivative, process for producing the same and use thereof |
| 02/17/2005 | WO2005014575A1 Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists |
| 02/17/2005 | WO2005014572A1 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | WO2005014571A1 Substituted piperidines as histamine h3 receptor ligands |
| 02/17/2005 | WO2005014563A1 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors |
| 02/17/2005 | WO2005014558A1 Condensed pyramidine compounds as inhibitors of voltage-gated ion channels |
| 02/17/2005 | WO2005014557A1 Tetrahydroquinazoline derivatives as cfr antagonists |
| 02/17/2005 | WO2005014554A1 1h-indazole-3-carboxamide compounds as mapkap kinase modulators |
| 02/17/2005 | WO2005014553A1 Novel gamma-secretase inhibitors |
| 02/17/2005 | WO2005014039A2 Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative diseases |
| 02/17/2005 | WO2005014033A1 Use of human growth hormone in multiple system atrophy |
| 02/17/2005 | WO2005014007A1 Compounds for the treatment of autoimmune and demyelinating diseases |
| 02/17/2005 | WO2005014001A1 Use of 2h- [1, 3] - oxazino [3, 2-a] indole derivatives for the treatment of neuropathic pain |
| 02/17/2005 | WO2005013997A1 Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists |
| 02/17/2005 | WO2005013989A1 Use of indazole derivatives for the treatment of neuropathic pain |
| 02/17/2005 | WO2005013986A1 Pyridylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | WO2005013985A1 Treatment for alzheimer's disease and related conditions |
| 02/17/2005 | WO2005013974A1 1-sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands |
| 02/17/2005 | WO2005013969A1 Antipsychotic agent with socializing properties |
| 02/17/2005 | WO2005013966A1 Macrophage activation inhibitor |
| 02/17/2005 | WO2005013961A1 Combination therapy for treatment of cognitive disorders or psychoses |
| 02/17/2005 | WO2005013954A1 Modified release venlafaxine hydrochloride tablets |
| 02/17/2005 | WO2005013953A1 Extended release venlafaxine besylate tablets |
| 02/17/2005 | WO2005013952A1 Therapeutic use of bicycloheptane derivatives |
| 02/17/2005 | WO2005013938A1 Process for producing drug ultramicroparticle and apparatus therefor |
| 02/17/2005 | WO2004110400A3 Implantable polymeric device for sustained release of nalmefene |
| 02/17/2005 | WO2004110344A3 New azetidine compounds |
| 02/17/2005 | WO2004089351A3 Treatment of progressive neurological disorders comprising a mao inhibitor (miclobemid) and an acetylcholinesterase inhibitor (tacrin) |
| 02/17/2005 | WO2004070050A3 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors |
| 02/17/2005 | WO2004016578A8 Arylethanolamine beta2-adrenoreceptor agonist compounds |
| 02/17/2005 | WO2003106449A8 Novel aryl-{4-halo-4-[heteroarylmethylamino)-methyl]-piperidin-1-yl}-methanone derivatives, methods for production and use thereof as medicaments |
| 02/17/2005 | WO2003099192A8 Bis-aromatic alkanols |
| 02/17/2005 | WO2003080568A3 Probucol derivatives |
| 02/17/2005 | WO2003050258A3 Endogenous retrovirus polypeptides linked to oncogenic transformation |
| 02/17/2005 | WO2003025131A3 Protein modification and maintenance molecules |
| 02/17/2005 | WO2002074913A3 Nucleic acid-associated proteins |
| 02/17/2005 | US20050038118 Treatment |
| 02/17/2005 | US20050038095 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 02/17/2005 | US20050038088 N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands |
| 02/17/2005 | US20050038087 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
| 02/17/2005 | US20050038084 Phenylalanine enamide derivatives |
| 02/17/2005 | US20050038072 Nitrogeneous cyclic ketone derivative, process for producing the same, and use |
| 02/17/2005 | US20050038069 Tumor necrosis factor antagonist; antiinflammatory agents; such as 2-Cyclopropyl-4-(3,5-dimethyl-4-pyridylmethoxy)-7-methoxy-3H-benzimidazole |
| 02/17/2005 | US20050038062 Methods and materials for the treatment of pain comprising opioid antagonists |
| 02/17/2005 | US20050038061 6-Aminomorphinane derivatives, method for production and use thereof |
| 02/17/2005 | US20050038060 Spiropoperidine compounds as ligands for orl-1 receptor |
| 02/17/2005 | US20050038055 Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists |
| 02/17/2005 | US20050038052 Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists |
| 02/17/2005 | US20050038046 Synergistic enhancement of cognitive ability |
| 02/17/2005 | US20050038045 A2B adenosine receptor antagonists |
| 02/17/2005 | US20050038042 Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders |
| 02/17/2005 | US20050038040 Corticotropin releasing factor antagonist; antiinflammatory agents; drug abuse; analgesics; antihistamines; skin disorders; neurodegenerative disease; eating disorders;eating disorders; antiepileptic agents; cardiovascular disorders |